Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sanqi Longxuejie Capsules in Stable Exertional Angina (Phase IV, Single-Arm)
ChiCTR2100053707Phase 4Recruiting
- Sponsor
- Xiyuan Hospital of China Academy of Chinese Medical Sciences
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Sanqi Longxuejie in coronary arteriosclerosis and stable angina, sponsored by Xiyuan Hospital of China Academy of Chinese Medical Sciences. Primary endpoints: Seattle Angina Questionnaire score and Incidence of adverse events. Started Nov 2021; status: recruiting.
02
Drugs
Sanqi Longxuejie
03
Conditions
coronary arteriosclerosisstable angina
Beyond the preview
Go deeper on ChiCTR2100053707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053707.